23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors. The target for the new investigational antibody, ULBP6, was discovered through 23andMe’s proprietary research platform, the world’s largest recontactable database of de-identified human genetic and phenotypic information. This is the third drug target genetically validated by the 23andMe research platform to enter the clinic in under 4 years.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks